North Carolina clinical research organization Clinipace Worldwide is flexing its muscles abroad with an executive hire that boosts the CRO’s European operations.
Dr. Jurgen Frisch has been named chief medical officer for Clinipace’s European operations. He will be based in the company’s offices in Zurich, Switzerland.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Clinipace, headquartered in Morrisville, North Carolina, has experienced considerable global growth in recent years from a series of acquisitions. The company got a foothold into Switzerland last year with its acquisition of Swiss firm PFC Pharma Focus. That deal also brought PFC’s sites in Germany, Israel and India. Clinipace expanded to Latin America with its 2009 acquisition of Worldwide Clinical Research, a Kansas-based CRO. Clinipace last fall closed a $15 million series C financing round led by Morgan Stanley Expansion Capital. Clinipace raised the money to support its global growth plans.
Frisch, who is board certified in internal medicine, brings to Clinipace experience from several pharmaceutical and biotechnology companies that include Eidetica Biopharma, a subsidiary of Biogen Idec (NASDAQ:BIIB). He has also worked as a medical reviewer for Switzerland’s therapeutics regulatory body Swissmedic.
